Rhumbline Advisers Lowers Stake in OPKO Health, Inc. (NASDAQ:OPK)

Rhumbline Advisers lowered its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 5.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 490,279 shares of the biotechnology company’s stock after selling 28,544 shares during the period. Rhumbline Advisers owned 0.07% of OPKO Health worth $814,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 8,064 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares in the last quarter. Comerica Bank increased its position in shares of OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 16,369 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of OPKO Health by 4.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 18,571 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on OPK shares. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. Finally, JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $2.75.

OPKO Health Price Performance

NASDAQ OPK opened at $1.29 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28. The stock’s fifty day moving average price is $1.35 and its 200 day moving average price is $1.52. OPKO Health, Inc. has a 1 year low of $1.19 and a 1 year high of $2.04. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -18.43 and a beta of 1.39.

OPKO Health (NASDAQ:OPK) last released its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same period in the previous year, the company earned ($0.12) earnings per share. OPKO Health’s revenue was down 13.7% on a year-over-year basis. As a group, equities research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were bought at an average cost of $1.65 per share, with a total value of $165,000.00. Following the transaction, the chief executive officer now owns 213,751,448 shares of the company’s stock, valued at approximately $352,689,889.20. This trade represents a 0.05% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have purchased 500,000 shares of company stock valued at $775,000. Company insiders own 49.69% of the company’s stock.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.